Clinical Trial Update: PD-1 Inhibitor Combined With Rituximab, Methotrexate, and Orelabrutinib (PD-1i+RMO) for Newly Diagnosed PCNSL and SCNSL. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating a PD-1 inhibitor in combination with Rituximab, Methotrexate, and Orelabrutinib for newly diagnosed Primary Central Nervo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• METHOTREXATE (METHOTREXATE)
• Orelabrutinib (orelabrutinib)
• PD-1 inhibitor
• Rituximab (rituximab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL) | Phase 2 | Status: RECRUITING